摘要
目的:探究去甲基化药物(hypomethylating agent,HMA)在骨髓增生异常综合征(myelodysplastic syndrome,MDS)伴或不伴骨髓纤维化(MF)患者治疗中的临床效果。方法:收集山西白求恩医院2017年1月—2023年9月收治的147例MDS患者,其中MF 0级患者50例,MF 1~3级患者97例。根据骨髓纤维化的严重程度将接受HMA单药治疗的患者分为2组,非纤维化组(MF 0级)27例,纤维化期组(MF 1~3级)59例;根据是否接受HMA单药治疗将MF 1~3级患者分为2组,支持治疗组30例,HMA单药治疗组59例。分别比较2组患者的年龄、性别、血液学指标(白细胞计数、中性粒细胞计数、血红蛋白、血小板计数)、骨髓原始细胞比例、根据IPSS-R与IPSS-M的危险分层、WHO 2016分型、基因突变(TP53、ASXL1、U2AF1、DNMT3A、SF3B1、TET2、JAK2、RUNX1)以及治疗疗效。结果:非纤维化组与纤维化期组年龄、白细胞计数、中性粒细胞计数、血红蛋白、骨髓原始细胞比例、根据IPSS-R与IPSS-M的危险分层以及基因突变比较,差异无统计学意义(P>0.05),性别、血小板计数、中位总生存期(overall survival,OS)与中位无进展生存期(progression-free survival,PFS),差异有统计学意义(P<0.05),对其中74例患者进行了疗效分析,差异无统计学意义(P>0.05);支持治疗组与HMA单药治疗组的年龄、性别、白细胞计数、中性粒细胞计数、血红蛋白以及中位OS、中位PFS比较,差异无统计学意义(P均>0.05),血小板计数、骨髓原始细胞比例、根据IPSS-R及IPSS-M的危险分层、WHO 2016分型、基因突变(ASXL1、TET2)差异有统计学意义(P<0.05)。结论:MDS中骨髓纤维化与预后不良有关。接受HMA单药治疗并不能改善MDS伴骨髓纤维化患者的预后,并且接受HMA单药治疗并不能延长MDS伴骨髓纤维化患者的OS和PFS。
Objective To explore the clinical efficacy of hypomethylating agent(HMA)in the treatment of patients with or without myelofibrosis(MF)in myelodysplastic syndrome(MDS).Methods 147 MDS patients admitted to Shanxi Bethune Hospital from January 2017 to September 2023 were collected,including 50 patients with MF grade 0 and 97 patients with MF grade 1-3.Patients treated with HMA were divided into two groups according to the severity of myelofibrosis,27 cases in the non-fibrotic group(MF 0)and 59 cases in the fibrotic phase group(MF 1-3);patients with MF grade 1-3 were divided into two groups according to whether they received HMA,30 cases in the supportive treatment group and 59 cases in the HMA group.Age,sex,hematological parameters(white blood cell count,neutrophil count,hemoglobin,platelet count),proportion of bone marrow blasts,risk stratification according to IPSS-R and IPSS-M,WHO 2016 classification,gene mutations(TP53,ASXL1,U2AF1,DNMT3A,SF3B1,TET2,JAK2,RUNX1)and treatment efficacy were compared between the two groups.Results There were no significant differences in age,white blood cell count,neutrophil count,hemoglobin,percentage of bone marrow blasts,risk stratification according to IPSS-R versus IPSS-M,and gene mutations between non-fibrotic and fibrotic groups(P>0.05),sex,platelet count,median overall survival and median progression-free survival,statistically significant(P<0.05),Seventy-four of these patients were analyzed for efficacy and there was no significant difference between subgroups(P>0.05);Supportive treatment vs HMA:There were no significant differences in age,sex,leukocyte count,neutrophil count,hemoglobin,and median overall survival versus median progression-free survival(P>0.05).Platelet count,proportion of bone marrow blasts,risk stratification according to IPSS-R and IPSS-M,WHO 2016 typing,and gene mutations(ASXL1,TET2)were statistically significant(P<0.05).Conclusion Myelofibrosis in MDS is associated with poor prognosis.Treatment with HMA alone did not improve outcomes in patients with MD
作者
祝坤
张婕
贡蓉
ZHU Kun;ZHANG Jie;GONG Rong(Shanxi Medical University Third Hospital,Shanxi Norman Bethune Hospital,Shanxi Academy of Medical Sciences,Tongji Shanxi Hospital,Taiyuan,030032,China)
出处
《临床血液学杂志》
CAS
2024年第5期333-338,共6页
Journal of Clinical Hematology
